The abstract discusses the significance of
Indoleamine-2,3-dioxygenase (IDO1) as a target for
cancer immunotherapy. There is a surge of interest in inhibiting the Trp-to-Kyn pathway to manage immunosuppression in various cancers. Pharmaceutical entities are actively pursuing clinical trials for IDO1 inhibitors such as
INCB024360,
GDC-0919,
indoximod, and
BMS-986205. Notably, at the 2017 ASCO Annual Meeting, it was highlighted that
head and neck squamous cell carcinoma patients showed positive responses to combinations involving epacadostat with
pembrolizumab and
nivolumab. Furthermore, epacadostat was found to be highly effective in combination with
PD-1 inhibitors for
solid tumors. The 32nd SITC annual meeting revealed promising early clinical trial results for BMS-986205 combined with Opdivo. The authors previously reported on the dual IDO1/
TDO inhibitor
DN131 and now introduce
DN-016, a more potent and selective IDO1 inhibitor with superior drug-like characteristics. DN-016, a novel heterocyclic compound, showed exceptional in vitro potency against hela IDO1 cells and favorable ADME properties. It also demonstrated high oral bioavailability in rat pharmacokinetic studies and is currently under preclinical evaluation both as a standalone treatment and in combination with a PD-1 inhibitor. The abstract concludes by emphasizing DN-016's remarkable in vitro potency, selectivity, and pharmacokinetic profile, with further preclinical data to be presented.
Reference: Chen S, Liu F, Guo H, et al. Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5555.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
